CONTENTS

Special Lecture

1079 There Are No Bad Anticancer Agents, Only Bad Clinical Trial Designs—Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Daniel D. Von Hoff.

Review Article


Advances in Brief


Research Articles


1147 Infrequent Expression of p21 Is Related to Altered p53 Protein in Pancreatic Carcinoma. Yu-Xin Hu, Hirouki Watanabe, Koushiro Ohtsubo, Yasushi Yamaguchi, Aiguli Ha, Yoshitharu Motoo, Takashi Okai, and Norio Sawabu.


1193 Phase I Study of Suramin Combined with Doxorubicin in the Treatment of Androgen-independent Prostate Cancer. Shi-Ming Tu, Lance C. Pagliaro, Marie E. Banks, Robert J. Amato, Randall E. Millikan, Nagla A. Bugazia, Timothy Madden, Robert A. Newman, and Christopher J. Logothetis.

1203 A Two-Part Phase I Trial of High-Dose Interleukin 2 in Combination with Soluble (Chinese Hamster Ovary) Interleukin 1 Receptor. David F. McDermott, Elizabeth G. Trehu, James W. Mier, Damian Sorce, William Rand, Lucie Ronayne, Kerry Kappler, Marguerite Clancy, Mark Klempner, and Michael B. Atkins.


1221 Evaluation of the Balance between Angiogenic and Antiangiogenic Circulating Factors in Patients with Breast and Gastrointestinal Cancers. Daniele Morelli, Debora Lazzerini, Sara Cazzaniga, Paolo Squicciarini, Paola Bignami, Jeanette A. M. Maier, Lucia Sfondrini, Sylvie Menard, Maria I. Colnaghi, and Andrea Balsari.

Patients with Isolated Trisomy 8 in Acute Myeloid Leukemia Are Not Cured with Cytarabine-based Chemotherapy: Results from Cancer and Leukemia Group B 8461. John C. Byrd, David Lawrence, Diane C. Arthur, Mark J. Pettenati, Ramana Tantravahi, Mazin Qumsiyeh, Judith Stamborg, Frederick R. Davey, Charles A. Schiffer, and Clara D. Bloomfield.


Loss of p21WAF1/Cip1 Protein Expression Accompanies Progression of Sporadic Colorectal Neoplasms but not Hereditary Nonpolyposis Colorectal Cancers. Frank A. Sinicrope, Gardiner Roddey, Michael Lemoine, Sanbao Ruan, L. Clifton Stephens, Marsha L. Frazier, Yu Shen, and Wei Zhang.


Antiangiogenic Chemotherapeutic Agents: Characterization in Comparison to Their Tumor Growth Inhibition in Human Renal Cell Carcinoma Models. Michael Schirmer, Jens Hoffmann, Andreas Menrad, and Martin R. Schneider.

Successful Treatment of Human Chronic Lymphocytic Leukemia Xenografts with Combination Biological Agents Auristatin PE and Bryostatin I. Ramzi M. Mohammad, Mary L. Varterasian, Victor P. Almatchy, Ghadeer N. Hannoudi, George R. Pettit, and Ayad Al-Katib.
